Skip to main content
OpenTrials
Completed

NCT Number: NCT03622502

The Effect of Dexmedetomidine for Emergence Cough

Dexmedetomidine or remifentanil are effective in attenuating cough during peri-extubation period after general anesthesia. The purpose of this study was to investigate the effect of dexmedetomidine on the remifentanil concentration for the cough suppression during anesthetic emergence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cough Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ajou University Hospital

Suwon, Gyeongki-do, 443-721, South Korea

About this study

Administration of dexmedetomidine before end of surgery could reduce airway reflexes and hemodynamic changes during tracheal extubation. Compared with remifentanil alone, administration of dexmedetomidine in combination with remifentanil is effective in relieving cough and hemodynamic changes without inhibition of respiration. The purpose of this study was to investigate the effect of dexmedetomidine on the remifentanil concentration for the cough suppression during anesthetic emergence using the modified up-and-down method.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ASA physical status I or II undergoing endoscopic sinus surgery or septoplasty under general anesthesia

Exclusion criteria

  • predicted difficult airway
  • body mass index > 35 kg/m2,
  • recent upper respiratory infection
  • asthma
  • current smoker
  • patients using angiotensin converting enzyme-inhibitors
  • uncontrolled hypertension

Treatment and study plan

Dexmedetomidine

Drug

Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery

Other names: Prededex

Remifentanil

Drug

Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)

Other names: Ultiva

normal saline

Drug

Normal saline was infused over 10 min before end of the surgery

Other names: 0.9% NaCl

Primary outcomes

  1. Number of cough

    Time frame: from end of surgery to 5 min after tracheal extubation]

    Number of cough or a strong and sudden contraction of the abdomen during periextubation periextubation periods

Sponsors and collaborators

Lead sponsor

Ajou University School of Medicine

Other

Registry information

Official study title

The Effect of Dexmedetomidine on the Remifentanil Concentration for Preventing Cough During Emergence After Propofol Anesthesia

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 9, 2018
Registry last updated
Jan 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.